A study to compare the incidence of hematological toxicities between bone marrow sparing - intensity modulated radiotherapy and conventional intensity modulated radiotherapy in treatment of carcinoma of uterine cervix.
Not Applicable
- Conditions
- Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
- Registration Number
- CTRI/2024/07/071465
- Lead Sponsor
- Sri Venkateswara Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
•Carcinoma cervix of International Federation of Gynaecologist and Obstetrician (FIGO) Stage IB1 – IVA.
•Patients of age group 18 years and older.
•Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
•Patients with Hb more than 10 g/dl, TC - more than 4000 cells/cu.mm, PLT - more than 1.5 lakh/cu.mm.
•Patients who has given approved informed consent.
Exclusion Criteria
•Patients with ECOG performance status of 3-4.
•Patients with distant metastasis.
•Patients with prior EBRT and/or Brachytherapy to pelvis.
•Pregnant women and lactating mothers.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Grades of hematological toxicity by using Radiation Therapy Oncology Group (RTOG) scoring criteria such as <br/ ><br>•Leukopenia <br/ ><br>•Neutropenia <br/ ><br>•Thrombocytopenia <br/ ><br>•Anemia <br/ ><br>Timepoint: From the Day 1 of treatment to 6 weeks. <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method Dosimetry by Dose Volume Histogram (DVH) such as <br/ ><br> LSS – V10 & mean dose <br/ ><br> PB – V10, 20, 40 & mean dose <br/ ><br> LSS marrow – V10, 20, 40 & mean dose <br/ ><br> PB marrow – V10, 20, 40 & mean dose <br/ ><br> HIP marrow – V10, 20, 40 & mean dose <br/ ><br>Timepoint: •On Day 1 of Treatment.